Quality of life after ultra-hypofractionated radiotherapy for prostate cancer: the challenge of RTOG 0938 trial

Abstract

In the Red Journal , Lukka and colleagues reported optimal quality of life (QoL) outcomes of the NRG Oncology RTOG 0938 trial (1). This trial randomly compared two short radiation schedules of 5 and 12 fractions of 7.25 and 4.3 Gy each, respectively, for the treatment of localized, low risk prostate cancer. The primary endpoint was the proportion of patients with a change in bowel and urinary EPIC-50 score at 1-year.